Table.
Plasma/serum, age-specific paediatric reference intervals for total calcium, creatinine, insulin and oestradiol for various analytical platforms (determined as part of CALIPER pilot projects at the Hospital for Sick Children, Toronto).
| Abbott Diagnostics Architect ci8200 | Roche Diagnostics Cobas 6000 | Ortho Clinical Diagnostics (Fusion 5,1) | Siemens Immulite 2500 | DiaSorin Clinical Assays | |
|---|---|---|---|---|---|
| Calcium (mmol/L) | |||||
| Standardisation | NIST SRM 915 (Coulometric Titration) | NIST SRM 909b (ID/MS) | NIST SRM 915a (Flame AAS) | ||
| Methodology | Arsenazo III | O-cresolphthalein complexone | Arsenazo III | ||
| Reference intervals | |||||
| 0–12 months | F: 2.5 – 2.8 M: 2.3 – 2.8 | F: 2.29 – 3.08 M: 1.91 – 2.93 | <1 month: 2.00 – 2.75 | ||
| 1–5 years | 2.3 – 2.6 | F: 2.13 – 2.65 M: 2.19 – 2.77 | 1 mo – 11 mo: 2.17 – 2.70 | ||
| 6–10 years | 2.3 – 2.6 | 2.15 – 2.60 | 1 – 3 years: 2.17 – 2.65 | ||
| 11–14 years | 2.2 – 2.6 | 2.15 – 2.60 | ≥4 year: 2.19 – 2.60 | ||
| 15–20 years | 2.2 – 2.6 | 2.15 – 2.60 | |||
| Creatinine (μmol/L) | |||||
| Standardisation | NIST SRM 909 and 914 (IDMS) | IDMS | NIST SRM 914 (GC/IDMS) | ||
| Methodology | Kinetic Alkaline Picrate | Enzymatic | Enzymatic | ||
| Reference intervals | |||||
| 0–12 months | 30.2 – 47.7 | 15.7 – 35.1 | <6 days: 19 – 99 | ||
| 1–5 years | 30.9 – 52.2 | 16.4 – 43.0 | 7 days – 60 days: 10 – 56 | ||
| 6–10 years | F: 35.8 – 60.5 M: 45.7 – 63.2 | 25.8 – 55.3 | 2 months – 5 years: <36 | ||
| 11–14 years | F: 45.9 – 70.0 M: 46.3 – 72.2 | 29.4 – 72.1 | 6 – 9 years: <53 | ||
| 15–20 years | F: 51.3 – 80.9 M: 53.7 – 92.2 | F: 38.6 – 84.9 M: 35.6 – 95.6 | 10 – 13 years: <79 | ||
| ≥14 years: <98 | |||||
| Insulin (pmol/L) | |||||
| Standardisation | WHO NIBSC 1st IRP 66/403 | WHO NIBSC 1st IRP 66/403 | WHO NIBSC 1st IRP 66/403 | ||
| Methodology | One step chemiluminescent microparticle immunoassay | Biotinylated-Streptavidin chemiluminescent | Solid phase, two-site chemiluminescent | ||
| Reference intervals | |||||
| 0–12 months | 9.0 – 199.6 | 4.2 – 248.1 | <90 | ||
| 1–5 years | 4.8 – 205.6 | 1.59 – 233.4 | <118 | ||
| 6–10 years | 11.9 – 400.9 | 12.0 – 614.5 | <118 | ||
| 11–14 years | 18.3 – 754.3 | 12.0 – 614.5 | <118 | ||
| 15–20 years | 14.2 – 725.9 | 12.0 – 614.5 | <118 | ||
| Oestradiol (pmol/L) | |||||
| Standardisation | Abbott internal reference standard - verified against ID-GCMS | Standardised via ID-GCMS | Calibrated against in-house internal (99% purity) reference preparation | ||
| Methodology | Delayed one step chemiluminescent particle immunoassay | Biotinylated-Streptavidin chemiluminescent | Competitive Radioimmunoassay | ||
| Reference intervals | |||||
| 0–12 months | F: 28.2 – 155.9 M: 30.3 – 85.6 | F: 20.3 – 133.1 M: 11.8 – 77.9 | <11 month: 370 | ||
| 1–5 years | F: 31.7 – 97.8 M: 15.5 – 84.1 | F: 11.9 – 75.4 M: 14.2 – 68.1 | 1 year - adrenarche: <92 | ||
| 6–10 years | F: 30.3 – 137.8 M: 14.8 – 69.2 | F: 14.4 – 150.6 M: 13.0 – 77.1 | Adult: <165 | ||
| 11–14 years | F: 26.9 – 354.6 M: 28.8 – 113.4 | F: 29.8 – 600.1 M: 4.7 – 127.1 | Follicular phase: 110 – 183 | ||
| 15–20 years | F: 34.0 – 953.4 M: 29.6 – 181.9 | F: 29.5 – 576.5 M: 48.8 – 135.7 | Luteal phase: 550 – 845 | ||
| Treated with synthetic oestrogen: <165 | |||||